ROR1 and B-cell chronic lymphocytic leukemia: ROR1, one of the most promising cancer targets, is aberrantly expressed in numerous malignancies yet exhibits minimal expression in normal tissue, rendering it a viable candidate for CAR-T therapy.39 ROR1 may represent a tumor-specific target for treatment since it was found to be significantly expressed in B-cell chronic lymphocytic leukemia (B-CLL) but not in normal B cells.40 ROR1-targeted T-cell therapies could be advantageous in treating B-CLL and other ROR1-positive cancers.